^
    Back
    Association details:
    Biomarker:JAK3 mutation
    Cancer:T Acute Lymphoblastic Leukemia
    Drug:tofacitinib (JAK2 inhibitor, JAK1 inhibitor, JAK3 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Cold Spring Harb Mol Case Stud
    Title:

    Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations

    Published date:
    08/25/2020
    Excerpt:
    Despite the molecularly targeted rationale, tofacitinib did not induce an objective clinical response. Our report suggests that the presence of activating JAK3 mutations does not necessarily confer sensitivity to pharmacological JAK3 inhibition.
    DOI:
    10.1101/mcs.a004994